An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis.
Publication Title
Clinics in liver disease
Document Type
Article
Publication Date
11-1-2017
Keywords
Aftercare; Autoimmune Diseases; Cholagogues and Choleretics; Cholangitis; Disease Management; Disease Progression; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Ursodeoxycholic Acid
Abstract
Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by chronic granulomatous lymphocytic cholangitis of the small bile ducts. PBC was a leading indication for liver transplant in the United States; with early diagnosis and treatment, the majority of patients with PBC have a normal life expectancy. Pathogenesis involves inflammatory damage of bile duct epithelium secondary to innate and adaptive immune responses, and toxicity from accumulated bile acids. Cholestasis and disease progression can lead to cirrhosis. Extrahepatic complications include dyslipidemia, metabolic bone disease, and fat-soluble vitamin deficiency. Ursodeoxycholic acid is a well-established therapy. Novel targeted therapeutics are being developed.
Clinical Institute
Digestive Health
Specialty/Research Institute
Gastroenterology
Specialty/Research Institute
Hepatology
